Kurs & Likviditet
|Industri||Läkemedel & Handel|
|2022-04-08||Ordinarie utdelning DANCAN 0.00 DKK|
|2021-07-23||Extra Bolagsstämma 2021|
|2021-04-29||Ordinarie utdelning DANCAN 0.00 DKK|
COPENHAGEN, Denmark, 19 March 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company") hereby announce that Magnus Østergaard Dahlmann has chosen to transfer the position of Chairman of the Board of Directors of the biopharmaceutical company DanCann Pharma A/S to Carsten Trads due to health reasons. Magnus Østergaard Dahlmann will continue as a member of the company's Board of Directors.
The change of chairmanship is quite undramatic and is due to a desire from Magnus Østergaard Dahlmann to disengage resources in connection with a long-term course of treatment, and subsequently the Board of Directors has chosen to distribute the tasks differently.
- DanCann Pharma is developing rapidly right now. Therefore, the company needs a chairman who can put the necessary number of hours into the task, and I will not be able to do this in the coming months. Fortunately, the presidency is in good hands with Carsten and I am pleased to be allowed to continue our co-operation in the Board of Directors as a member, Magnus Østergaard Dahlmann says.
The new chairman is quite confident with his new position and does not expect major changes in the day-to-day work of the Board of Directors.
- We fully understand that Magnus will have to focus intensively on getting well. However, we are utterly grateful that he finds our joint project so exciting that he would like to stay on the Board of Directors, where we will certainly benefit from his great knowledge, Carsten Trads emphasizes.
About DanCann Pharma
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
For further information, please contact:
Carsten Trads, Chairman of the Board at DanCann Pharma A/S